In breast cancer, EXOs displaying targeting ligands such as the GE11 peptide or A15 have been used to deliver chemotherapeutic agents and miRNAs to EGFR- or integrin α_vβ_3-expressing tumor cells, resulting in reduced tumor growth and limited off-target effects in vivo [149,150]. This evidence concerns the gene EGFR and neoplasm.